Objective. In addition to the controversy regarding the association of hyperuricemia with cardiovascular disease (CVD) mortality, few studies have examined the impact of a low uric acid level on mortality. We undertook the present study to evaluate the relationship between both low and high uric acid levels and the risk of allcause and cause-specific mortality in a large sample of Korean adults over a full range of uric acid levels.
Uric acid is the final oxidation product of purine metabolism and is an established risk factor for gouty arthritis and kidney stones (1) . A number of epidemiologic studies have shown that an elevated uric acid level is associated with a wide variety of adverse health outcomes, including hypertension, metabolic syndrome, kidney disease, cardiovascular disease (CVD), and cancer (2) (3) (4) (5) (6) . However, the role of uric acid as an independent risk factor for CVD, cancer, and all-cause mortality remains a subject of controversy (7) (8) (9) (10) (11) . Some studies demonstrated a positive association between hyperuricemia and cardiovascular mortality (12, 13) , while other studies did not (14, 15) . Furthermore, studies of the association between serum uric acid level and cancer mortality have provided conflicting results. Taghizadeh et al reported that a high level of uric acid was related to a lower risk of cancer mortality (16) . In contrast, other cohort studies demonstrated that a high level of uric acid was associated with an increased risk of cancer-related mortality (17, 18) .
Most studies of the association between the uric acid level and mortality have focused on the role of hyperuricemia, but the influence of a low uric acid level on mortality has not been established. A cohort study in Japan demonstrated that low uric acid level (<4.6 mg/dl in men and <3.3 mg/dl in women) can increase CVD mortality (5) .
Recently, several studies have shown that a low uric acid level was significantly associated with increased all-cause mortality in patients undergoing dialysis (19, 20) . The uric acid has an antioxidant effect (21) , and it has been demonstrated that hypouricemia can injure the endothelium and induce oxidative stress-related disease such as hypertension, diabetes mellitus, and kidney disease (22, 23) . Few longitudinal studies have evaluated the risk of all-cause, cancer-specific, and CVD mortality across the full range of uric acid levels in the general population while considering both low and high uric acid levels. The purpose of this study was to evaluate the association of low and high uric acid levels with all-cause, CVD, and cancer-specific mortality in a large cohort of Korean adults who participated in a health screening examination program.
PATIENTS AND METHODS
Study population. The Kangbuk Samsung Health Study is a cohort study of Korean men and women who underwent comprehensive annual or biennial health examinations at the Kangbuk Samsung Hospital Total Healthcare Centers in Seoul and Suwon, South Korea (24, 25) . The current cohort included all men and women age ≥18 years who participated in a screening between January 1, 2002 and December 31, 2012 (n = 375,163). More than 80% of participants were employees of various companies and local government organizations and their spouses. In Korea, annual or biennial health screening examinations of employees are required by the Industrial Safety and Health Law.
We excluded 22,120 subjects who met one of the following exclusion criteria: unknown vital status (n = 2); missing data on uric acid level, glucose level, body mass index (BMI), or estimated glomerular filtration rate (GFR) (n = 320); a history of malignancy (n = 5,352); and/or a history of CVD (n = 16,643). Because some participants met more than one exclusion criterion, the total number of participants eligible for this study was 375,163. This study was approved by the institutional review board of Kangbuk Samsung Hospital. The requirement for informed consent was waived, because we used de-identified retrospective data routinely collected during the health screening process.
Data collection. All examinations were conducted at a Kangbuk Samsung Hospital Total Healthcare Center in Seoul or Suwon. Self-administered standardized questionnaires were used to identify medical history and medication use, smoking status, alcohol intake, and exercise frequency (24, 25) . CVD and malignancy were defined as physician-diagnosed heart disease or stroke and physician-diagnosed malignancy of any type, respectively. Smoking status was categorized as never, former, and current. Alcohol consumption was categorized as none, moderate (<20 gm/day), and high (≥20 gm/day). We also assessed the weekly frequency of moderate-or vigorous-intensity physical activity.
Sitting blood pressure (BP), height, and weight were measured by trained nurses. Body mass index (BMI) was calculated as the weight in kilograms divided by the height in meters squared. Obesity was defined as a BMI ≥25 kg/m 2 , which is the proposed cutoff for Asian populations (26) . Hypertension was defined as systolic BP ≥140 mm Hg, diastolic BP ≥90 mm Hg, or current use of antihypertensive medication.
Blood specimens were obtained from the antecubital vein after more than 10 hours of fasting. Serum levels of glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, creatinine, total bilirubin, and gamma glutamyl transferase (GGT) were measured at the Laboratory Medicine Department of Kangbuk Samsung Hospital as previously described (25) . Serum uric acid levels were measured enzymatically using an automatic analyzer (either an Advia 1650 Auto analyzer [Bayer Diagnostics] or a Modular DP analyzer [Roche Diagnostics]). Insulin resistance was assessed with the homeostatic model assessment of insulin resistance (HOMA-IR) equation: fasting blood insulin (lU/ml) 9 fasting blood glucose (mmoles/liter)/22.5. Diabetes mellitus was defined as a fasting serum glucose level ≥126 mg/dl or current use of medication to treat diabetes mellitus.
We estimated GFR using the 4-variable Modification of Diet in Renal Disease study equation (27) Chronic kidney disease was defined as an estimated GFR <60 ml/minute/1.73 m 2 . Mortality follow-up. The vital status of study subjects was identified through nationwide death certificate data from the Korea National Statistical Office through December 31, 2012. According to the registry for the Domestic Relations Act in Korea, all deaths of Koreans are reported to Statistics Korea, meaning that death certificate data among Korean adults can be considered 100% accurate. Concordance between the cause of death according to the death certificate and diagnosis based on medical utilization data (the death benefit record of the Korean Medical Insurance Corporation) was 72.2% for all-cause deaths and 94.9% for deaths from cancer of all sites, regardless of primary site (28) .
CVD mortality was defined as International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes I00 to I99. Cancer deaths were identified by ICD-10 codes C00-C97 as the underlying cause of death on the death certificates (29) .
Statistical analysis. The chi-square test and one-way analysis of variance were used to compare the characteristics of the study participants at baseline regarding categories of uric acid level in men and women. There is no universally accepted definition of hypouricemia or hyperuricemia solely based on uric acid level, while sex differences regarding uric acid levels are well described in a previous report (30) . Therefore, sex-specific values based on the uric acid distribution of our population were used in this study. Men were divided into 8 groups according to uric acid level in mg/dl (<3. , and ≥8.5). The reference group was defined as the lowest mortality incidence group in both men and women (6.5-7.4 mg/dl in men and 3.5-4.4 mg/dl in women). Hazard ratios (HRs) with 95% confidence intervals (95% CIs) for mortality outcomes were estimated using Cox proportional hazards regression analysis. We used age as the time scale where subjects enter the analysis at their age at the time of their first health check-up examination (left Table 1 . 
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We used 2 models with progressively increased adjustments for confounding variables that could affect the association between uric acid level and mortality. We initially adjusted for study center (Seoul, Suwon), year of screening examination (1-year categories), education level (less than college education, college education or more, or unknown), alcohol intake (none, <20 gm/day, ≥20 gm/day, or unknown), smoking (never, past, current, or unknown), vigorous exercise (<3 times/week, ≥3 times/week, or unknown), and BMI (continuous). Next, we included history of hypertension (yes, no, or unknown), diabetes mellitus (yes, no, or unknown), medication for hyperlipidemia (yes, no, or unknown), medication for hypertension (yes, no, or unknown), and estimated GFR (continuous). We assessed the proportional hazards assumption by examining graphs of estimated log(Àlog) (survival). For tests of a quadratic trend, we squared the linear trend variable after centering it on the reference value in both men and women. To further explore the shape of the dose-response relationship between the uric acid level and the risk of all-cause, CVD, and cancer mortality, restricted cubic splines with knots were used at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles of uric acid distribution.
Finally, we performed stratified analyses in the prespecified subgroups defined by smoking status (never or past smoker versus current smoker), alcohol intake (<20 gm/day versus ≥20 gm/day), obesity (BMI <25 kg/m 2 versus ≥25 kg/m 2 ), HOMA-IR value (<2.5 versus ≥2.5), chronic kidney disease (no versus yes), diabetes mellitus (no versus yes), and any comorbidities including hypertension, diabetes mellitus, and chronic kidney disease (no versus yes); interactions between subgroups were tested using likelihood ratio tests comparing models with and those without multiplicative interaction terms. All P values were 2-tailed, and P values less than 0.05 were considered significant. We used Stata software, version 14.0 (StataCorp) for data analysis.
RESULTS
Baseline characteristics of men and women are described in Tables 1 and 2 , respectively. Serum uric acid levels were higher in men than in women. In men and women, an increase in serum uric acid level was positively associated with increased BMI, obesity, alcohol consumption, hypertension, elevated systolic and diastolic BP, total cholesterol, LDL cholesterol, triglycerides, HOMA-IR value, high-sensitivity C-reactive protein level, GGT level, and homocysteine level. An increase in the serum uric acid level was negatively associated with age and HDL cholesterol in men and with higher education level and HDL cholesterol in women. Serum uric acid levels increased with age in women but not in men.
The median follow-up duration was 5.7 years (interquartile range 2.3-8.7 years). There were 2,020 deaths documented during 2,060,721.9 person-years of follow-up (1,439 in men and 581 in women). Among the total deaths, 287 were ascribed to CVD (206 in men and 81 in women) and 963 to cancer (683 in men and 280 in women). Table 3 shows the relationship between serum uric acid level and risks of all-cause, CVD, and cancer mortality in men. In a multivariable model adjusted for center, year of screening examination, education level, BMI, smoking status, alcohol intake, regular exercise, hypertension, diabetes mellitus, medication for hyperlipidemia, and estimated GFR, the lowest level of uric acid (<3.5 mg/dl) was associated with increased risk of all-cause, CVD, and cancer mortality in men. The corresponding HRs for all-cause, CVD, and cancer mortality comparing <3.5 mg/dl uric acid with 6.5-7.4 mg/dl uric acid were 1.58 (95% CI 1.18-2.10), 1.50 (95% CI 0.62-3.64), and 1.38 (95% CI 0.91-2.11), respectively. The highest level of uric acid (≥9.5 mg/dl) was also significantly associated with increased risk of all-cause, CVD, and cancer mortality in men. The multivariableadjusted HRs for all-cause, CVD, and cancer mortality comparing ≥9.5 mg/dl uric acid with 6.5-7.4 mg/dl uric acid were 2.39 (95% CI 1.57-3.66), 3.76 (95% CI 1.54-9.20), and 2.67 (95% CI 1.47-4.87), respectively.
The lowest level of uric acid (<2.5 mg/dl) was associated with increased risk of all-cause, CVD, and cancer mortality in women (Table 4 ). The multivariable-adjusted HRs for all-cause, CVD, and cancer mortality comparing <2.5 mg/dl uric acid with 3.5-4.4 mg/dl uric acid were 1.80 (95% CI 1.10-2.93), 3.96 (95% CI 1.37-11.47), and 1.58 (95% CI 0.76-3.29), respectively. The highest level of uric acid (≥8.5 mg/dl) was associated with significantly increased risk of all-cause and CVD mortality, but a significant difference in cancer mortality was not observed. The multivariable-adjusted HRs for all-cause and CVD mortality comparing ≥8.5 mg/dl uric acid with 3.5-4.4 mg/dl uric acid were 377 (95% CI 1.17-12.17) and 11.44 (95% CI 2.74-47.68), respectively.
In multivariable-adjusted spline regression models for both men and women, a U-shaped association between uric acid and all-cause mortality was observed at~7 mg/dl for men and~4 mg/dl for women, as an inflection point (Figures 1 and 2) . In prespecified subgroup analyses, associations between serum uric acid level and mortality were similar across subgroups of study participants with no significant interactions with regard to alcohol intake (<20 gm/day versus ≥20 gm/day), smoking status (never versus current), regular exercise (<3 times/week versus ≥3 times/week), BMI (<25 kg/m 2 versus ≥25 kg/m 2 ), HOMA-IR value (<2.5 versus ≥2.5), chronic kidney disease (no versus yes), diabetes mellitus (no versus yes), or comorbidities including hypertension, diabetes mellitus, and chronic kidney disease (no versus yes) (see Supplementary Tables 1 and 2, available <0.001 * See Table 1 for definitions. † Among 9,666 women with homocysteine measurements.
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In a sensitivity analysis, we reanalyzed the association between uric acid and mortality in men and women after excluding those age >60 years. The results did not change qualitatively (see Supplementary Tables 3 and 4 , http:// onlinelibrary.wiley.com/doi/10.1002/art.40472/abstract).
DISCUSSION
In this large cohort study of young and middleaged men and women, both low and high uric acid levels were significantly associated with increased mortality compared with the sex-specific reference group. This association remained statistically significant after further adjusting for potential confounders including estimated GFR. Our findings suggest a U-shaped, independent association between serum uric acid level and mortality in both men and women.
In contrast to our findings, a recent study showed no association between uric acid levels and all-cause or cardiovascular mortality (14) . In that study, uric acid was categorized according to quintiles (≤5.2, 5.3-5.8, 5.9-6.4, 6.5-7.1, and >7.1 mg/dl in men and ≤3.5, 3.6-4.0, 4.1-4.4, 4.5-5.0, and >5.0 mg/dl in women). While a quintile-based analytic approach is a commonly used method in epidemiologic research (31) , by grouping uric acid levels according to quintiles, intracategory variation in mortality risk could not be examined, leading to the failure to detect the influence of very low and very high uric acid levels on mortality. The upper bound of the lowest uric acid quintile in that study was higher than that in our study, while the lower bound of the highest quintile was much lower than that in our study.
The Evidence for Cardiovascular Prevention from Observational Cohorts in Japan study of 36,313 subjects showed increased CVD mortality associated with low uric acid level in men but not in women, using a quintilebased approach (5); the lowest level of uric acid was defined as <4.6 mg/dl in men and <3.3 mg/dl in women. That study did not take into account several confounding factors such as glucose and creatinine levels, which were † Cox proportional hazards models using age as a time scale were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs). Model 1 was adjusted for age (time scale). Model 2 was further adjusted for center, year of screening examination, education level, body mass index, smoking status, alcohol intake, and regular exercise. Model 3 was further adjusted for hypertension, diabetes mellitus, use of medication for hyperlipidemia, use of medication for hypertension, and estimated glomerular filtration rate.
unavailable. Approximately two-thirds of serum uric acid is excreted by the kidneys, and uric acid level is affected by renal function. It was difficult to determine whether the association between the uric acid level and mortality observed in previous studies was independent of decreased renal function as well as other confounders (32) . Recently, a cohort study of 27,490 participants with normal kidney function demonstrated that a low uric acid level was an independent risk factor for all-cause mortality in men, while high uric acid levels were not (15); for women, there was no significant association between serum uric acid levels and mortality (15) . In our study, an association between low uric acid level (<3.5 mg/dl in men and <2.5 mg/dl in women) and all-cause mortality was found in both men and women and remained significant after adjustment for estimated GFR. A low uric acid level was also significantly associated with increased risk of cancer mortality in men (Table  3 , models 1 and 2) and increased CVD mortality in women (Table 4 , models 1-3), while a nonsignificant increase in CVD mortality among men and in cancer mortality among women was observed. Our findings were consistent with those from earlier studies that showed U-shaped or J-shaped associations. A Taiwanese study showed U-shaped associations between uric acid levels and all-cause mortality and cardiovascular mortality in the general population (33) . That study used the reference group of uric acid level (5-6 mg/dl) to evaluate low (<2.9 mg/dl) and high (>11.4 mg/dl) uric acid levels. However, that study was limited by the absence of important covariates such as smoking status, alcohol intake, and BMI. We found a U-shaped association after adjusting for these factors. Another small Taiwanese study showed a J-shaped association with all-cause mortality in patients receiving hemodialysis (34) . Patients with low (<6.5 mg/dl) or high (>9.0 mg/dl) uric acid levels had a higher risk of mortality, with the highest risk at higher levels. A J-shaped association between serum uric acid level and poor renal survival was recently reported in patients with nephropathy (35). † Cox proportional hazards models using age as a time scale were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs). Model 1 was adjusted for age (time scale). Model 2 was further adjusted for center, year of screening examination, education level, body mass index, smoking status, alcohol intake, and regular exercise. Model 3 was further adjusted for hypertension, diabetes mellitus, use of medication for hyperlipidemia, use of medication for hypertension, and estimated glomerular filtration rate.
1128 CHO ET AL Figure 1 . Multivariable-adjusted hazard ratios for all-cause (A), cardiovascular disease (CVD) (B), and cancer mortality (C) by uric acid level among men. Blue lines represent adjusted hazard ratios (with 95% confidence limits [dashed lines]) for all-cause, CVD, and cancer mortality based on restricted cubic splines with knots at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles of uric acid distribution. Red lines represent references for hazard ratios. Models were adjusted for age (time scale), center, year of screening examination, smoking status, alcohol intake, physical activity, education level, body mass index, hypertension, diabetes mellitus, use of medication for hyperlipidemia, use of medication for hypertension, and estimated glomerular filtration rate. ) for all-cause, CVD, and cancer mortality based on restricted cubic splines with knots at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles of uric acid distribution. Red lines represent references for hazard ratios. Models were adjusted for age (time scale), center, year of screening examination, smoking status, alcohol intake, physical activity, education level, body mass index, hypertension, diabetes mellitus, use of medication for hyperlipidemia, use of medication for hypertension, and estimated glomerular filtration rate.
Even though the mechanism underlying the increased risk of mortality related to a low uric acid level is not fully understood, there are some possible explanations. Low uric acid level can also be a marker of nutrition, possibly reflecting malnutrition (36) . Unfortunately, the current study was not able to include nutritional information. Additionally, information about medication use that could affect uric acid levels was unavailable. However, our study population comprised young or middleaged people with low levels of comorbid conditions including diabetes mellitus, hypertension, and renal diseases; thus, the observed association of low uric acid level and mortality might not be fully explained by unmeasured confounders. Indeed, uric acid acts as an antioxidant by increasing superoxide dismutation to hydrogen peroxide and decreasing the availability of superoxide and its harmful interaction with nitric oxide (37) . Individuals with hypouricemia are hypothesized to develop increased risk of atherosclerotic diseases due to decreased antioxidant potential (38, 39) . The induction of cancer cell proliferation was observed in low uric acid conditions through reactive oxygen species (ROS) production in a mouse model (40) . Further study is warranted to elucidate the mechanism underlying the role of low uric acid levels in adverse health outcomes.
A high uric acid level was associated with increased all-cause mortality and CVD mortality (3, 12, 41) , while it was not associated with all-cause mortality in some previous studies (14, 15) . In our large cohort study, subjects in the groups with the highest uric acid levels (≥9.5 mg/dl in men and ≥8.5 mg/dl in women) showed a significantly increased risk of all-cause and CVD mortality. The association was stronger in women, even though the absolute incidence of all-cause and CVD mortality was >2 times higher in men. Similarly, previous population-based studies found a stronger association between hyperuricemia and CVD mortality, more so among women than among men (12, 13) . The mechanism behind hyperuricemiarelated all-cause and CVD mortality can be explained by inflammasome and oxidative stress. Hyperuricemia can activate the NLRP3 inflammasome and induce the production of interleukin-1b (42) . These events stimulate the inflammatory cascade reaction. Intracellular hyperuricemia also generates inflammatory stress from ROS/ reactive nitrogen species (RNS) generation and cyclooxygenase 2 (COX-2) activation. Oxidative stress with activation of the renin-angiotensin system in human vascular endothelial cells is the main mechanism of uric acid-induced endothelial dysfunction (43) . Genetic variants related to serum uric acid level were reported previously by the Global Urate Genetics Consortium (44) . Using Mendelian randomization with reported genetic variants, Kleber et al demonstrated that a high uric acid level is causally related to adverse cardiovascular outcomes (45) . As their study focused on subjects with European ancestry, analysis of related health outcomes with a genetic variant in an Asian population is needed.
Additionally, in our study, increased risk of cancer mortality was observed only in men with the highest uric acid levels and not in women; however, this inconclusive result for women might be explained by the small number of outcome events, which could lead to imprecise estimates. Elevated serum uric acid levels have been reported to be associated with excess cancer occurrence, recurrence, and cancer mortality in several studies (17, 46, 47) . High uric acid levels contribute to tumorigenesis by promoting both transformation and tumor cell proliferation mediating progression from early stage cancer to highly aggressive cancer (48) . This effect is thought to generate inflammatory stress arising from ROS/RNS generation and COX-2 activation. Hyperuricemia is also regarded as a consequence of high tumor cell proliferation rate and accelerated purine breakdown (48, 49) . The observed positive association between high uric acid level and cancer mortality may be due to the aggressive cancer status (50, 51) . Future studies are needed to assess the role of uric acid in cancer development, its progression, and related mortality while considering both low and high uric acid levels.
This study has several limitations. First, we did not adjust for dietary factors and drug histories. Data on urate-lowering medications were not available. The target uric acid level is <6 mg/dl during urate-lowering therapy according to the 2012 American College of Rheumatology guidelines for management of gout (52) . The mean uric acid-lowering effect is 2.7 mg/dl in hyperuricemic patients (53) . Furthermore, a very low level of uric acid (such as <3 mg/dl) is not recommended for gout management (54) . Therefore, a uric acid level below 3.5 mg/dl in men and 2.5 mg/dl in women, which were the lowest in our study, might not be affected by treatment. Second, repeated serum uric acid measurement data were not used. We used a single assessment of uric acid levels at baseline and did not incorporate changes in uric acid levels or other changes in lifestyle factors and covariates during follow-up. Third, information on smoking, alcohol use, physical activity, and medical history was obtained via a self-administered structured questionnaire used in health check-up programs in Korea as part of the National Health Insurance Program, and measurement error in these variables could have resulted in some degree of residual confounding.
Fourth, the significant findings are primarily driven by extreme categories of uric acid with a small number of events, as shown in Tables 3 and 4 . Fluctuations in uric acid levels are multifactorial: BMI, waist circumference, BP, insulin resistance, renal disease, diet, medication use, and genetic factors are all known to contribute to the variability of uric acid levels (55). Although we cannot exclude the possibility of unmeasured or residual confounding factors, our results were derived from a young Asian population and thus might have been less likely to be affected by comorbidities. Another possibility is that low extreme and high extreme levels of uric acid could be explained by genetic factors (56) (57) (58) . The prevalence of hypouricemia was reported to be 1.39% in Korea, which is higher than that reported in Western countries (59) . Finally, the subjects included in this study were young and middle-aged Korean men and women who regularly attended health screening examinations, most often as part of work-related health check-up programs; thus, generalization of these results to other age or race/ethnicity groups should be undertaken with caution.
Despite these limitations, the considerable strengths of this study included its large sample size and the use of carefully standardized clinical, imaging, and laboratory procedures. These strengths enabled researchers to examine the relationship between uric acid and cause-specific mortality across a full range of uric acid levels independently of possible confounders.
In conclusion, our study demonstrated that low uric acid levels were independently associated with increased risk of all-cause mortality in men and women, increased risk of CVD mortality in women, and increased risk of cancer mortality in men. Our study supports a J-or U-shaped association between serum uric acid levels and all-cause mortality, CVD mortality, and cancer mortality.
